![Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/attachment/418fc973-9e86-48ff-98dc-4d4d2addb9b0/gr2.gif)
Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology
![American Gastroenterological Association medical position statement: Short bowel syndrome and intestinal transplantation - ScienceDirect American Gastroenterological Association medical position statement: Short bowel syndrome and intestinal transplantation - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0016508503000520-gr1.jpg)
American Gastroenterological Association medical position statement: Short bowel syndrome and intestinal transplantation - ScienceDirect
![PDF] Short Bowel Syndrome in Adults - Part 4 B A Guide to Front Line Drugs Used in the Treatment of Short Bowel Syndrome | Semantic Scholar PDF] Short Bowel Syndrome in Adults - Part 4 B A Guide to Front Line Drugs Used in the Treatment of Short Bowel Syndrome | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/cda9dfe6906c3f0d91377e068f0345d419ab6477/3-Table1-1.png)